158.285 de modificări
Regeneron Pharmaceuticals Inc. (modificare)
Versiunea de la data 18 septembrie 2024 20:24
, 18 septembriefără descrierea modificării
Admin (discuție | contribuții) (csv2wiki) |
Admin (discuție | contribuții) Fără descriere a modificării |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei Regeneron Pharmaceuticals Inc. listata cu simbolul US.REGN | Pagina dedicata companiei Regeneron Pharmaceuticals Inc. listata cu simbolul US.REGN | ||
| Linia 5: | Linia 4: | ||
Regeneron Pharmaceuticals, Inc. (https://www.regeneron.com/) is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. | Regeneron Pharmaceuticals, Inc. (https://www.regeneron.com/) is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. | ||
==Grafic actiuni companie== | |||
<iframe key="tradeville" path="graficSimbol/US.REGN" /> | |||
==Ultimele stiri despre Regeneron Pharmaceuticals Inc. (US.REGN)== | ==Ultimele stiri despre Regeneron Pharmaceuticals Inc. (US.REGN)== | ||
| Linia 13: | Linia 14: | ||
addfirstcategorydate=false | addfirstcategorydate=false | ||
</dynamicpagelist> | </dynamicpagelist> | ||
[[Categorie:US.REGN]][[Categorie:Stiri despre companii]] | [[Categorie:US.REGN]][[Categorie:Stiri despre companii]] | ||